Novo Inks $600M Deal with Metaphore to Develop Next-Gen Obesity Drugs

Novo Nordisk on Thursday entered into a research collaboration agreement with the Flagship-founded Metaphore Biotechnologies to develop up to two next-generation GLP-1 receptor agonists for the treatment of obesity.